CA
NZ
UK
AU
IND
US
Oxford Lane Capital Corp.(NASDAQ:OXLC)released its financial results for the second fiscal quarter ended September 30, 2025, alongside the declaration of monthly distributions on common stock for the first quarter of calendar year 2026.
Milestone Pharmaceuticals Inc.NASDAQ:MISTannounced that it will present new clinical data from its investigationaletripamil nasal spray program for paroxysmal supraventricular tachycardia at the American Heart Association Scientific Sessions 2025 in New Orleans, Louisiana.
Vir Biotechnology, Inc.NASDAQ:VIRhas completed participant enrollment in ECLIPSE 1, a Phase 3 clinical study evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) currently holds an average rating of“Reduce”as reported by MarketBeat Ratings. The review is based on evaluations from eight research firms.
4D Molecular Therapeutics (Nasdaq:FDMT) announced an exclusive licensing agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the Asia-Pacific (APAC) region, including Japan, China, Australia, and other markets.
Takeda Pharmaceutical Company Limited(NYSE:TAK)announced results for the first half of fiscal year 2025, covering the six months ended September 30, 2025. Revenue fell 3.9% at constant exchange rate and 6.9% at actual exchange rate, mainly due to the generic erosion of VYVANSE® and the …
Argenx SE(NASDAQ:ARGX)released its financial results for the third quarter ended September 30, 2025, reporting total operating income of USD 1.2B, compared with USD 0.6B in the same quarter of 2024. The growth was primarily driven by higher product sales of VYVGART, which recorded USD …
Castle Biosciences, Inc.(NASDAQ:CSTL)presented new research at the American College of Gastroenterology 2025 Annual Scientific Meeting in Phoenix, Arizona, highlighting the ability of its TissueCypher® Barrett’s Esophagus test to deliver actionable risk assessments that inform individualized clinical decisions and enable earlier, risk-based interventions for patients …
The latest analysis, expanding the company’s 2023 data, examined a cohort of 20,000 patients and reaffirmed previous findings on the effectiveness of the Shield blood-based colorectal cancer screening test. Shield, the first FDA-approved blood test for primary CRC screening among average-risk adults aged 45 …
Nanobiotix(NASDAQ:NBTX)reported updates on the JNJ-1900 clinical program following the transfer of NANORAY-312 Phase 3 trial sponsorship and operational control to Johnson & Johnson. The transfer, which began in 3Q2024, covers most regions and includes full operational oversight of the trial.
Please wait processing your request...